Formulation-specific PA and diagnostic confirmation

Prior authorization must identify the specific testosterone formulation requested (oral, nasal, intramuscular, patch, gel, pellet, or subcutaneous) and provide documentation of symptomatic hypogonadism and a supporting total testosterone measurement consistent with trial selection (testosterone level ≤300 ng/dL). The request should include clinical rationale for the chosen formulation given differing absorption, dosing frequency, and route-specific adverse-effect profiles.

• List the formulation requested (oral, nasal, IM, patch, gel, pellet, subcutaneous).
• Include documentation of symptoms/signs of hypogonadism and a measured total testosterone value (≤300 ng/dL as used in cited RCTs).
• Explain rationale for formulation choice considering absorption, dosing frequency, and route-specific risks.

Attest symptomatic low testosterone and absence of exclusions

Prior authorization must attest the patient has symptomatic hypogonadism with a documented low total testosterone consistent with trial inclusion (≤300 ng/dL or the NIH trials’ <275 ng/dL) and confirm that trial-based exclusionary conditions (e.g., prostate cancer history, high prostate-cancer risk, IPSS >19, conditions causing hypogonadism, or high cardiovascular risk) are absent.

• Documented total testosterone value used for decision (≤300 ng/dL or <275 ng/dL where applicable).
• Statement that exclusionary conditions (history of prostate cancer, high prostate cancer risk, IPSS >19, conditions known to cause hypogonadism, high cardiovascular risk) are not present.

Document clinical population and rationale

Prior authorization should document the specific clinical population for which therapy is intended (for example, androgen deficiency on chronic steroid therapy or androgen deficiency with type 2 diabetes) and provide supporting evidence that therapy targets the relevant outcomes (symptoms, body composition, functional measures, or metabolic labs).

• Identify population (e.g., chronic steroid-associated androgen deficiency; androgen deficiency with type 2 diabetes).
• Describe targeted outcomes (symptom relief, lean body mass, HbA1c or other metabolic measures) and supporting evidence rationale.

Indication-specific prior authorization

Prior authorization must specify the indication (e.g., androgen deficiency with type 2 diabetes or older men with low testosterone without definite hypogonadism) and reference the relevant outcomes and laboratory parameters to be used to evaluate benefit (for example, sexual symptoms, functional outcomes, or HbA1c where applicable).

• State the indication population (type 2 diabetes; older men with low testosterone without definite hypogonadism).
• List outcomes or labs that will be used to assess benefit (sexual symptoms, functional measures, metabolic labs such as HbA1c).

Rationale: limited benefit and mixed safety data

Prior authorization rationale should note that evidence shows limited clinical benefit for many outcomes in men without clear hypogonadism and that cardiovascular and prostate safety data are mixed or uncertain; authorization should therefore verify documented low testosterone with clinical correlation and consider cardiovascular/prostate risk factors before approval.

• Acknowledge limited benefits for functional outcomes in men without pathologic hypogonadism.
• Document consideration of cardiovascular and prostate risk when weighing approval.

Product selection per guideline recommendation

When possible, prescribe commercially manufactured testosterone products rather than compounded preparations and avoid alkylated oral testosterone in accordance with guideline recommendations.

• Prefer commercially manufactured testosterone products over compounded products.
• Do not prescribe alkylated oral testosterone.

Codes provided for reference — coverage contingent on plan terms

The policy lists CPT/HCPCS/ICD-10 and other codes for reference; inclusion of a code does not guarantee coverage or reimbursement and authorization decisions remain subject to the member-specific benefit plan and the written medical policy.

• Codes are provided for general reference only and may not be all-inclusive.
• Presence of a code does not imply coverage; benefits depend on plan terms and the medical policy.

Formulation selection: consider route-specific factors

Select formulations with documented clinical rationale considering factors such as dosing frequency, absorption variability, and site- or route-specific adverse effects (e.g., liver toxicity with some oral agents, variable absorption with IM injections, skin irritation with patches, transmission risk with gels, surgical complications with pellets).

• Consider dosing frequency (daily topical vs. 10–14 week IM depot vs. 3–6 month pellets).
• Consider absorption variability and route-specific risks (liver toxicity for oral; inconsistent absorption for IM; skin irritation for patches; transmission risk for gels; implantation-site complications for pellets).

Step therapy: testosterone versus no testosterone (no sequencing mandated)

Step-therapy guidance notes that the primary comparator is no testosterone replacement; these sections do not prescribe a specific stepwise sequencing between formulations—authorization decisions should consider testosterone replacement versus conservative management.

• Therapy considered is testosterone replacement versus no testosterone.
• No specific mandatory sequencing between different testosterone formulations is provided in the policy.

Consider no testosterone replacement as comparator

Prior authorization should consider no testosterone replacement (watchful waiting or conservative management) as the comparator and document why conservative measures are insufficient before approving therapy.

• Describe conservative management tried or rationale for not pursuing non-treatment.
• Document why testosterone replacement is expected to provide benefit over no therapy.

Consider alternatives before initiating testosterone

Consider conservative (nonpharmacologic) alternatives before initiating testosterone in men without pathologic hypogonadism, given small and inconsistent benefits (mainly increased lean mass and decreased fat without consistent functional improvement).

• Document consideration or trial of nonpharmacologic alternatives when appropriate.
• Note that many trials showed increases in lean body mass and decreases in fat but not consistent functional gains.

Dose titration: target middle tertile of normal range

Clinicians should titrate testosterone dosing to achieve a total testosterone concentration in the middle tertile of the normal reference range, documenting dose adjustments and follow-up levels accordingly.

• Adjust dosing and document measured total testosterone targeted to the middle tertile of the normal range.
• Record dose changes and subsequent testosterone levels in the medical record.

Required clinical documentation: symptoms and confirmatory testosterone level

Documentation submitted with authorization must support symptomatic hypogonadism and include confirmatory laboratory testing consistent with trial criteria (total testosterone ≤300 ng/dL) and description of symptoms/signs used to establish hypogonadism.

• Provide a morning total testosterone result and note the assay if available.
• Describe clinical signs or symptoms that meet the definition of symptomatic hypogonadism.

Required documentation elements: baseline testosterone, symptoms, exclusions

Documentation should include baseline total testosterone level (trial eligibility thresholds used ≤300 ng/dL or <275 ng/dL), presence of symptoms/signs of hypogonadism, and note any exclusionary conditions (e.g., prostate cancer history, elevated IPSS).

• Include numeric baseline testosterone value and date/time (preferably morning sample).
• List presence of exclusionary conditions or confirm their absence.

Document diagnosis and clinical context for population of interest

Document the diagnostic context showing androgen deficiency in the population of interest (for example, androgen deficiency related to chronic steroid therapy or associated with type 2 diabetes) and include the rationale linking therapy to intended outcomes.

• Specify the clinical population (chronic steroid use, type 2 diabetes, older men without definite hypogonadism).
• Explain how testosterone therapy is expected to address the patient’s specific clinical problems.

Document which clinical population applies

For prior authorization, document whether the patient fits the evidence-based populations (e.g., androgen deficiency with type 2 diabetes or older men with low testosterone without definite hypogonadism) and indicate which population applies to the request.

• State which evidence-based population the patient represents.
• Include any population-specific details (e.g., comorbid diabetes) that influenced the decision to treat.

Document relevant clinical measures (PSA, hematocrit, body composition, function)

Document relevant baseline and follow-up clinical measures commonly reported in trials — for example, lean body mass, body fat, functional capacity, muscle strength, sexual symptoms, PSA, hematocrit, and metabolic parameters — as these inform efficacy and safety evaluation.

• Record baseline PSA and hematocrit and plan for periodic monitoring.
• Document measures of symptoms and functional outcomes used to assess benefit.

Baseline and monitoring evaluations per guideline guidance

Obtain a morning total testosterone using an accurate assay for baseline assessment; consider measuring sex hormone–binding globulin and pituitary hormones (LH, FSH) when indicated, and assess prostate-cancer risk before initiation with PSA and consider PSA and prostate monitoring 3–12 months after starting therapy in men aged 55–69 with life expectancy >10 years.

• Baseline: morning total testosterone; consider SHBG and LH/FSH if needed.
• Baseline PSA and hematocrit; plan PSA and hematocrit monitoring 3–12 months after initiation where guideline-recommended.

Coding guidance: codes are reference only

Codes listed in the policy are for general reference only; inclusion of a code does not guarantee coverage or reimbursement and plan-specific benefit determinations apply.

• Verify coverage and reimbursement based on the member’s specific benefit plan and the written medical policy, not solely on listed codes.

Denial risk: prescribing outside trial-based populations

Therapy prescribed outside the populations and diagnostic criteria used in the RCT-based systematic review (men with symptomatic hypogonadism and total testosterone ≤300 ng/dL) may be considered unsupported by the cited evidence and at higher risk for denial.

• If the patient does not meet symptomatic hypogonadism with testosterone ≤300 ng/dL, include justification and supporting evidence for off-trial–population use.

Exclusion criteria that may trigger denial

Exclusionary conditions used in NIH trials (history of prostate cancer, high prostate-cancer risk, IPSS >19, conditions known to cause hypogonadism, or high cardiovascular risk) were excluded from trial populations and their presence may trigger denial or require further evaluation.

• If any exclusionary condition is present, provide urologic or cardiology evaluation as appropriate before authorization.

Outcome-based denial risk: lack of demonstrated clinical benefit

Lack of demonstrated improvement in key outcomes (overall survival, symptoms, morbid events, functional outcomes, quality of life) is a potential basis for denial if evidence does not support benefit for the requested indication.

• Document objective outcome measures and expected clinical benefit to support approval.

Safety and evidence limitations in type 2 diabetes

In individuals with type 2 diabetes, benefits on glycemic and lipid measures have been reported but may be offset by increased risk of adverse events; selective reporting bias and short follow-up in trials are additional limitations that may influence coverage decisions.

• When treating men with diabetes, document careful consideration of risks versus metabolic benefits and cite supporting trial evidence.

Denial risk from uncertain risk–benefit (prostate/cardiovascular concerns)

Because the adverse-event profile (particularly potential prostate-related and cardiovascular harms) is uncertain in some populations (e.g., men without definite hypogonadism), these uncertainties can lead to denial or restriction when benefits are limited.

• Provide detailed risk assessment (cardiovascular and prostate) when benefits are expected to be marginal.

Contraindications and situations warranting avoidance

Do not prescribe testosterone therapy for men planning fertility in the near term, men with breast or prostate cancer, palpable prostate nodule or induration, PSA >4 ng/mL (or PSA >3 ng/mL with high prostate-cancer risk without further urologic evaluation), elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, recent myocardial infarction or stroke within 6 months, or thrombophilia.

• If any contraindicating condition is present, provide documentation and specialist evaluation if seeking an exception.

Coverage contingent on member-specific plan terms

Coverage and reimbursement determinations are contingent on member-specific benefit plan terms and the written medical policy; presence of listed codes does not guarantee payment.

• Confirm coverage through the member’s benefit plan and reference the medical policy when processing authorization or claims.